1. Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma
    Takaaki Higashi et al, 2016, Med Oncol CrossRef
  2. Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade
    Jiaoyuan Jia et al, 2017, PLoS ONE CrossRef
  3. Overexpression of Yes-associated protein and its association with clinicopathological features of hepatocellular carcinoma: A meta-analysis.
    Chengjie Lin et al, 2017, Liver Int CrossRef
  4. Early growth response 3 inhibits growth of hepatocellular carcinoma cells via upregulation of Fas ligand
    Shujuan Zhang et al, 2017 CrossRef
  5. Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A
    Madhuram Khandelwal et al, 2018, Mol Cell Biochem CrossRef
  6. The Role of Autophagy in Hepatocellular Carcinoma
    Yoo Lee et al, 2015, IJMS CrossRef
  7. null
    Yulei Zhao et al, 2019 CrossRef
  8. Yes-associated protein enhances proliferation and attenuates sensitivity to cisplatin in human gastric cancer cells
    Ting Lu et al, 2018, Biomedicine & Pharmacotherapy CrossRef
  9. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression
    Minjiang Chen et al, 2018, EBioMedicine CrossRef
  10. Yes-associated protein promotes the abnormal proliferation of psoriatic keratinocytes via an amphiregulin dependent pathway
    Jinjing Jia et al, 2018, Sci Rep CrossRef
  11. Molecular evidence for better efficacy of hypocrellin A and oleanolic acid combination in suppression of HCC growth
    Lin Wang et al, 2018, European Journal of Pharmacology CrossRef
  12. Yes-Associated Protein Contributes to the Development of Human Cutaneous Squamous Cell Carcinoma via Activation of RAS
    Jinjing Jia et al, 2016, Journal of Investigative Dermatology CrossRef
  13. Cluster of Differentiation 166 (CD166) Regulated by Phosphatidylinositide 3-Kinase (PI3K)/AKT Signaling to Exert Its Anti-apoptotic Role via Yes-associated Protein (YAP) in Liver Cancer
    Lifang Ma et al, 2014, J. Biol. Chem. CrossRef
  14. The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells
    Chang-En Yang et al, 2019, Chemico-Biological Interactions CrossRef
  15. High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway
    Hyuk Moon et al, 2019, IJMS CrossRef
  16. DYSREGULATION OF THE HIPPO PATHWAY SIGNALING IN AGING AND CANCER
    Yiu To Yeung et al, 2019, Pharmacological Research CrossRef
  17. YAP/TAZ Signaling and Resistance to Cancer Therapy
    Chan D.K. Nguyen et al, 2019, Trends in Cancer CrossRef
  18. miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells
    T Higashi et al, 2015, Br J Cancer CrossRef
  19. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.
    Randy Johnson et al, 2014, Nat Rev Drug Discov CrossRef
  20. Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
    Philamer C. Calses et al, 2019, Trends in Cancer CrossRef
  21. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Ping-Chih Hsu et al, 2019, IJMS CrossRef
  22. Activation of β-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice
    Junyan Tao et al, 2014, Gastroenterology CrossRef
  23. YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer
    Fredrik Jerhammar et al, 2014, Oral Oncology CrossRef
  24. The Hippo pathway in chemotherapeutic drug resistance
    Yulei Zhao et al, 2015, Int. J. Cancer CrossRef
  25. Hippo signaling pathway in liver and pancreas: the potential drug target for tumor therapy
    Delin Kong et al, 2015, Journal of Drug Targeting CrossRef
  26. Tumour promotion versus tumour suppression in chronic hepatic iron overload
    Steven A. Bloomer et al, 2015, Cell Biochem Funct CrossRef
  27. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial–mesenchymal transition
    Tao Xu et al, 2016, Cancer Letters CrossRef
  28. CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma
    Shigeki Suemura et al, 2019, Cancers CrossRef
  29. null
    Cathie M. Pfleger, 2017 CrossRef
  30. The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action
    Xuan Shi et al, 2017, Cancer Letters CrossRef
  31. Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling
    Yujie Li et al, 2019, Arch Toxicol CrossRef
  32. RASSF1A–Hippo pathway link in patients with urothelial carcinoma of bladder: plausible therapeutic target
    Madhuram Khandelwal et al, 2019, Mol Cell Biochem CrossRef
  33. Involvement of Yes‐associated protein 1 (YAP1) in doxorubicin‐induced cytotoxicity in H9c2 cardiac cells
    Akira Takaguri et al, 2019, Cell Biol Int CrossRef
  34. NUAK2 localization in normal skin and its expression in a variety of skin tumors with YAP
    Hind Al-Busani et al, 2020, Journal of Dermatological Science CrossRef
  35. The YAP signaling pathway promotes the progression of lymphatic malformations through the activation of lymphatic endothelial cells
    Wenqun Zhong et al, 2020, Pediatr Res CrossRef
  36. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP
    Yu Tian et al, 2016, Oncotarget CrossRef
  37. YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways
    Daniel Andrade et al, 2017, Oncotarget CrossRef
  38. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo
    Dan Sun et al, 2016, Oncotarget CrossRef
  39. YAP and 14-3-3γ are involved in HS-OA-induced growth inhibition of hepatocellular carcinoma cells: A novel mechanism for hydrogen sulfide releasing oleanolic acid
    Guanglin Xu et al, 2016, Oncotarget CrossRef
  40. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway
    Meiyuan Chen et al, 2015, Oncotarget CrossRef
  41. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer
    Qiongrong Chen et al, 2015, Oncotarget CrossRef
  42. YAP is a critical oncogene in human cholangiocarcinoma
    Tiemin Pei et al, 2015, Oncotarget CrossRef
  43. Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells
    Jiayi Wang et al, 2015, Oncotarget CrossRef
  44. The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
    Ping-Chih Hsu et al, 2020, Cancers (Basel) CrossRef
  45. miR‑149‑5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway.
    Manman Xu et al, 0 CrossRef
  46. Chemoresistance‑related long non‑coding RNA expression profiles in human breast cancer cells
    Lei Huang et al, 2018, Mol Med Report CrossRef
  47. Downregulation of YAP inhibits proliferation, invasion and increases cisplatin sensitivity in human hepatocellular carcinoma cells.
    Xiaoguang Wang et al, 2018, Oncol Lett CrossRef
  48. Role of YAP in lung cancer resistance to cisplatin
    Juan Song et al, 2018, Oncol Lett CrossRef
  49. A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma
    Shumei Song et al, 2018, Mol Cancer Ther CrossRef
  50. The Hippo Signaling Pathway in Drug Resistance in Cancer
    Renya Zeng et al, 2021, Cancers CrossRef
  51. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer
    Na-Hyun Lee et al, 2021, Biomedicines CrossRef
  52. miR‑375/Yes‑associated protein axis regulates IL‑6 and TGF‑β expression, which is involved in the cisplatin‑induced resistance of liver cancer cells
    Kanru Yu et al, 2021, Oncol Rep CrossRef
  53. A Yes-Associated Protein (YAP) and Insulin-Like Growth Factor 1 Receptor (IGF-1R) Signaling Loop Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma
    Mai-Huong T. Ngo et al, 2021, Cancers CrossRef
  54. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer
    Hina Qayoom et al, 2021, Future Oncology CrossRef
  55. Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib.
    Wei Xu et al, 2015, Cell Biosci CrossRef
  56. The dual role of microRNA-9 in gastrointestinal cancers: oncomiR or tumor suppressor?
    Afsane Bahrami et al, 2022, Biomedicine & Pharmacotherapy CrossRef
  57. Drug-Resistant Breast Cancer: Dwelling the Hippo Pathway to Manage the Treatment
    Simran Kaur et al, 2021, BCTT CrossRef
  58. Transcriptional co‐activators YAP1–TAZ of Hippo signalling in doxorubicin‐induced cardiomyopathy
    Tünde Berecz et al, 2021, ESC Heart Failure CrossRef
  59. null
    Ankit Banik et al, 2022 CrossRef
  60. N6-Methyladenosine Reader YTHDF2 Enhances Non-Small-Cell Lung Cancer Cell Proliferation and Metastasis through Mediating circ_SFMBT2 Degradation
    Jing Xu et al, 2022, Contrast Media & Molecular Imaging CrossRef
  61. Yes-Associated Protein and Transcriptional Coactivator with PDZ-Binding Motif in Cardiovascular Diseases
    Ruojun Li et al, 2023, IJMS CrossRef
  62. Dysregulated YAP1/Hippo Pathway Contributes to Doxorubicin (ADM) Resistance in Acute Myeloid Leukemia (AML)
    Yan Song et al, 2023, CPB CrossRef
  63. YAP1 Recognizes Inflammatory and Mechanical Cues to Exacerbate Benign Prostatic Hyperplasia via Promoting Cell Survival and Fibrosis
    Dongxu Lin et al, 2023, Advanced Science CrossRef
  64. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
    Xiaoting Luo et al, 2024, MedComm CrossRef
  65. Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers
    Hongge Liang et al, 2024, Cancer Gene Ther CrossRef
  66. Genetic dependencies associated with transcription factor activities in human cancer cell lines
    Venu Thatikonda et al, 2024, Cell Reports CrossRef